Genoa Pharmaceuticals Receives Orphan-Drug Designation for Pirfenidone in the Inhaled Treatment of Idiopathic Pulmonary Fibrosis

Aug 6, 2014, 10:59 AM
PFF Comment
Daniel M. Rose, MD, Chief Executive Officer

"We are pleased to provide this recent press release from Genoa Pharmaceuticals.  Please note that this therapy proposes to deliver pirfenidone in an “inhaled” form.  This is different from the pifenidone (Esbriet®) that has been developed by InterMune which is available in an oral tablet form. Additionally the inhaled therapy is still in early stage development and requires further clinical evaluation to assess its efficacy.”

View Genoa Pharmaceuticals Press Release
footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >